Jiangsu Hengrui Pharmaceuticals (1276.HK) Earnings Analysis
Jiangsu Hengrui Pharmaceuticals (1276.HK) next reports earnings on 2026-08-17, consensus EPS 0.4388 HKD. Last quarter (2026-04-22) it beat with EPS 0.3897 HKD vs 0.3747 HKD est (+4%). It has beaten estimates in 1/2 recent quarters (50%). Trailing P/E 43.93.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 1276.HK next report earnings?
| Next earnings date | 2026-08-17 |
|---|---|
| Consensus EPS estimate | 0.4388 HKD |
| Revenue estimate | 10.34B |
1276.HK earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-04-22 | 0.3897 HKD | 0.3747 HKD | +4% | Beat |
| 2026-03-25 | 0.3401 HKD | 0.3906 HKD | -12.9% | Miss |
Beat rate: 1/2 (50%) over reported quarters with consensus data.
1276.HK valuation and analyst view
| Trailing P/E | 43.93 |
|---|---|
| Trailing EPS | 1.231 HKD |
| Price / book | 5.69 |
| Dividend yield | 0.36% |
| Market cap | 381.64B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Jiangsu Hengrui Pharmaceuticals (1276.HK)'s next earnings date?
Jiangsu Hengrui Pharmaceuticals is next scheduled to report on 2026-08-17, with a consensus EPS estimate of 0.4388 HKD and revenue estimate of 10.34B.
Did 1276.HK beat earnings last quarter?
In its 2026-04-22 report, 1276.HK posted EPS of 0.3897 HKD versus a 0.3747 HKD estimate — a beat of 4%.
What is 1276.HK's earnings track record?
Over the last 2 reported quarters with consensus data, 1276.HK beat estimates 1 times (50%).
What is 1276.HK's current P/E ratio and EPS?
1276.HK trades at a trailing P/E of 43.93 on trailing EPS of 1.2305598766115993 HKD.
What do analysts rate 1276.HK?
1276.HK has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.